The exploitation of toll-like receptor 3 signaling in cancer therapy

Current Pharmaceutical Design

Volumn 20, Issue 42, 2014, Pages 6555-6564

  Glavan, Tanja Matijević ^a   Pavelić, Jasminka ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cancer; Poly (I: C); Signaling; Therapy; Toll like receptor 3

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; MDA5 PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; RINTATOLIMOD; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); HUMAN; MALIGNANT NEOPLASTIC DISEASE; PROTEIN LOCALIZATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; AGONISTS; DRUG EFFECTS; METABOLISM; NEOPLASMS;

HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 84911468481     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826153347     Document Type: Article

References (73)

1. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894-901.
2. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002; 293: 1364-9.
3. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320: 379-81.
4. Leonard JN, Ghirlando R, Askins J, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci USA 2008; 105: 258-63.
5. Matsumoto M, Funami K, Oshiumi H, Seya T. Toll-IL-1-receptor-containing adaptor molecule-1: a signaling adaptor linking innate immunity to adaptive immunity. Prog Mol Biol Transl Sci 2013; 117: 487-510.
6. Sarkar SN, Elco CP, Peters KL, Chattopadhyay S, Sen GC. Two tyrosine residues of Toll-like receptor 3 trigger different steps of NF-kappa B activation. J Biol Chem 2007; 282: 3423-7.
7. Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in doublestranded RNA signaling. Nat Struct Mol Biol 2004; 11: 1060-7.
8. Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 2005; 174: 4942-52.
9. Hornung V, Ellegast J, Kim S, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994-7.
10. Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008; 205: 1601-10.
11. Jin B, Sun T, Yu XH, et al. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol 2010; 2010: 690438.
12. Furrie E, Macfarlane S, Thomson G, Macfarlane GT. Toll-like receptors-2,-3 and-4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005; 115: 565-74.
13. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009; 58: 1375-85.
14. DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012; 2012: 785825.
15. Samara KD, Antoniou KM, Karagiannis K, et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol 2012; 40: 1397-404.
16. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Tolllike receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13(15 Pt 1): 4565-74.
17. Gonzalez-Reyes S, Marin L, Gonzalez L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010; 10: 665.
18. Pries R, Hogrefe L, Xie L, et al. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008; 21: 209-15.
19. Chew V, Tow C, Huang C, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012; 104: 1796-807.
20. Matijevic T, Marjanovic M, Pavelic J. Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol 2009; 70: 18-24.
21. Matijevic T, Pavelic J. The dual role of TLR3 in metastatic cell line. Clin Exp Metastasis 2011; 28: 701-12.
22. Chuang JH, Lin TK, Tai MH, et al. Preferential involvement of mitochondria in Toll-like receptor 3 agonist-induced neuroblastoma cell apoptosis, but not in inhibition of cell growth. Apoptosis 2012; 17: 335-48.
23. Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008; 29: 1334-42.
24. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007; 100: 1301-12.
25. Estornes Y, Toscano F, Virard F, et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ 2012; 19: 1482-94.
26. Sun R, Zhang Y, Lv Q, et al. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J Biol Chem 2011; 286: 15918-28.
27. Galli R, Paone A, Fabbri M, et al. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression. Proc Natl Acad Sci USA 2013; 110: 9812-7.
28. Yoneda K, Sugimoto K, Shiraki K, et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008; 33: 929-36.
29. McCall KD, Harii N, Lewis CJ, et al. High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 2007; 148: 4226-37.
30. Schwartz AL, Malgor R, Dickerson E, et al. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 2009; 15: 4114-22.
31. Paone A, Galli R, Gabellini C, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hy-poxia-inducible factor 1 alpha. Neoplasia 2010; 12: 539-49.
32. Thuringer D, Jego G, Wettstein G, et al. Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. Faseb J 2013; Jun 26. [Epub ahead of print].
33. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011; 60: 217-26.
34. Friboulet L, Gourzones C, Tsao SW, et al. Poly(I: C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells. BMC Cancer 2010; 10: 327.
35. Friboulet L, Pioche-Durieu C, Rodriguez S, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 2008; 10: 1183-94.
36. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 2010; 17: 942-51.
37. Gomaz A, Pavelic J, Matijevic Glavan T. The polymorphisms in Toll-like receptor genes and cancer risk. Period Biol 2012; 114: 461-9.
38. He JF, Jia WH, Fan Q, et al. Genetic polymorphisms of TLR3 are associated with nasopharyngeal carcinoma risk in Cantonese population. BMC Cancer 2007; 7: 194.
39. Castro FA, Forsti A, Buch S, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 2011; 47: 1203-10.
40. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst 1976; 57: 599-602.
41. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I). poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994; 18 Suppl 1: S88-95.
42. Gowen BB, Wong MH, Jung KH, et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I: C12U), but not Poly(I: C): differential recognition of synthetic dsRNA molecules. J Immunol 2007; 178: 5200-8.
43. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C(12)U] (Ampligen R). Vaccine 2003; 21: 787-90.
44. Navabi H, Jasani B, Reece A, et al. A clinical grade poly I: C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 2009; 27: 107-15.
45. Berge M, Bonnin P, Sulpice E, et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 2010; 177: 3192-201.
46. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol 2012; 188: 5357-64.
47. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010; 70: 2595-603.
48. Shime H, Matsumoto M, Oshiumi H, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012; 109: 2066-71.
49. Bever CT, Jr., Salazar AM, Neely E, et al. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology 1986; 36: 494-8.
50. Levy HB, Baer G, Baron S, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132: 434-9.
51. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007; 5: 10.
52. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012; 18: 6497-508.
53. Perrot I, Deauvieau F, Massacrier C, et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol 2010; 185: 2080-8.
54. Jeung HC, Moon YW, Rha SY, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A: U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008; 19: 520-6.
55. Laplanche A, Alzieu L, Delozier T, et al. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat 2000; 64: 189-91.
56. Lacour J, Laplanche A, Malafosse M, et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992; 18: 599-604.
57. Matijevic T, Kirinec G, Pavelic J. Antitumor activity from the combined application of poly(I: C) and chemotherapeutics in human metastatic pharyngeal cell lines. Chemotherapy 2011; 57: 460-7.
58. Jiang Q, Wei H, Tian Z. Poly I: C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008; 8: 12.
59. Park JH, Jeon DI, Yoon HE, et al. Poly I: C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma. Acta Odontol Scand 2012; 70: 241-5.
60. Van DN, Roberts CF, Marion JD, et al. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. Faseb J 2012; 26: 3188-98.
61. Taura M, Eguma A, Suico MA, et al. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol 2008; 28: 6557-67.
62. Taura M, Fukuda R, Suico MA, et al. TLR3 induction by anticancer drugs potentiates poly I: C-induced tumor cell apoptosis. Cancer Sci 2010; 10: 1610-7.
63. Verillaud B, Gressette M, Morel Y, et al. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A: U) combined to a Smac-mimetic. Infect Agent Cancer 2012; 7: 36.
64. Bernardo AR, Cosgaya JM, Aranda A, Jimenez-Lara AM. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis 2013; 4: e479.
65. Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J Immunother 2012; 35: 670-9.
66. Amos SM, Pegram HJ, Westwood JA, et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates es tablished melanoma in mice. Cancer Immunol Immunother 2011; 60: 671-83.
67. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E. BiVax: a pep-tide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother 2013; 62: 787-99.
68. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 2009; 69: 9012-9.
69. Wu CY, Yang HY, Monie A, et al. Intraperitoneal administration of poly(I: C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol Immuno-ther 2011; 60: 1085-96.
70. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 2006; 3: e6.
71. Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res 2011; 17: 1033-43.
72. Abourbeh G, Shir A, Mishani E, et al. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life 2012; 64: 324-30.
73. Service of the U. S. National Institutes of Health. Available from: http://clinicaltrials. gov/.